Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 1/2011

01-02-2011 | Original Article

Gaucher disease in sheep

Authors: Litsa Karageorgos, Malcolm J. Lancaster, Judith S. Nimmo, John J. Hopwood

Published in: Journal of Inherited Metabolic Disease | Issue 1/2011

Login to get access

Abstract

Gaucher disease, an autosomal recessive lysosomal storage disorder caused by mutations in the β-glucocerebrosidase gene, was recently discovered in sheep on a “Southdown” sheep stud in Victoria, Australia. Clinical signs include neuropathy, thickened leathery skin, and ichthyosis, with lambs unable to stand from birth. Affected lambs were found to be deficient in glucocerebrosidase activity, and mutational analysis found them to be homozygous for the missense mutations c.1142G>A (p.C381Y) and c.1400C>T (p.P467L). In addition, four silent mutations were detected (c.777C>A [p.Y259Y], c1203A>G [p.Q401Q], c.1335T>C [p.I445I], c.1464C>G [p.L488L]). The human equivalent [C342Y] to the C381Y mutation leads to an acute neuronopathic phenotype in patients. Identification of an acute neuronopathic form of Gaucher disease in sheep provides a large animal model that will enable studies of pathology and evaluation of therapies to treat this common lysosomal storage disorder.
Literature
go back to reference Barneveld RA, Keijzer W, Tegelaers FP, Ginns EI, Geurts van Kessel A, Brady RO, Barranger JA, Tager JM, Galjaard H, Westerveld A, Reuser AJ (1983) Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies. Hum Genet 64:227–31CrossRefPubMed Barneveld RA, Keijzer W, Tegelaers FP, Ginns EI, Geurts van Kessel A, Brady RO, Barranger JA, Tager JM, Galjaard H, Westerveld A, Reuser AJ (1983) Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies. Hum Genet 64:227–31CrossRefPubMed
go back to reference Beutler E, Gelbart T, Scott CR (2005) Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 35:355–364CrossRefPubMed Beutler E, Gelbart T, Scott CR (2005) Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 35:355–364CrossRefPubMed
go back to reference Choy FYM, Vaags A, Wong K, Macgregor D, Fernandez B, Prasad C (2002) Identification of two novel mutations, L105R and C342R in type I Gaucher disease. Clin Genet 61:229–231CrossRefPubMed Choy FYM, Vaags A, Wong K, Macgregor D, Fernandez B, Prasad C (2002) Identification of two novel mutations, L105R and C342R in type I Gaucher disease. Clin Genet 61:229–231CrossRefPubMed
go back to reference Eyal N, Wilder S, Horowitz M (1990) Prevent and rare mutations among Gaucher patients. Gene 96:277–83CrossRefPubMed Eyal N, Wilder S, Horowitz M (1990) Prevent and rare mutations among Gaucher patients. Gene 96:277–83CrossRefPubMed
go back to reference Grafe MR, Thomas C, Schneider JA, Katz B, Wiley C (1988) Infantile Gaucher's disease: a case with neuronal storage. Ann Neurol 23:300–303CrossRefPubMed Grafe MR, Thomas C, Schneider JA, Katz B, Wiley C (1988) Infantile Gaucher's disease: a case with neuronal storage. Ann Neurol 23:300–303CrossRefPubMed
go back to reference Hartley WJ, Blakemore WF (1973) Neurovisceral glucoceregroside storage (Gaucher’s disease) in a dog. Vet Pathol 10(1):91–201 Hartley WJ, Blakemore WF (1973) Neurovisceral glucoceregroside storage (Gaucher’s disease) in a dog. Vet Pathol 10(1):91–201
go back to reference Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E (1989) The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 4(1):87–96CrossRefPubMed Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E (1989) The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 4(1):87–96CrossRefPubMed
go back to reference Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 5:567–83CrossRef Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 5:567–83CrossRef
go back to reference Enquist IB, Nilsson E, Ooka A, Månsson JE, Olsson K, Ehinger M, Brady RO, Richter J, Karlsson S (2006) Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci USA 103:13819–24CrossRefPubMed Enquist IB, Nilsson E, Ooka A, Månsson JE, Olsson K, Ehinger M, Brady RO, Richter J, Karlsson S (2006) Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci USA 103:13819–24CrossRefPubMed
go back to reference Laws L, Saal JR (1968) Lipidoses of the hepatic reticuloendothelial cells in a sheep. Aust Vet J 44:416–417CrossRefPubMed Laws L, Saal JR (1968) Lipidoses of the hepatic reticuloendothelial cells in a sheep. Aust Vet J 44:416–417CrossRefPubMed
go back to reference Leech RW, Shuman RM, Putnam WD, Rance F (1985) Jewett TT (1985) Gaucher's disease: a case history with extensive lipid storage in the brain. Am J Clin Pathol 83:516–519PubMed Leech RW, Shuman RM, Putnam WD, Rance F (1985) Jewett TT (1985) Gaucher's disease: a case history with extensive lipid storage in the brain. Am J Clin Pathol 83:516–519PubMed
go back to reference Naito M, Takahashi K, Hojo H (1988) An ultrastructural and experimental study on the development of tubular structures in the lysosomes of Gaucher cells. Lab Invest 58:590–598PubMed Naito M, Takahashi K, Hojo H (1988) An ultrastructural and experimental study on the development of tubular structures in the lysosomes of Gaucher cells. Lab Invest 58:590–598PubMed
go back to reference Sandison AJ, Anderson LJ (1970) Histocytosis of two pigs and a cow: Conditions resembling lipid storage diseases in man. J Pathol 100:207–210CrossRefPubMed Sandison AJ, Anderson LJ (1970) Histocytosis of two pigs and a cow: Conditions resembling lipid storage diseases in man. J Pathol 100:207–210CrossRefPubMed
go back to reference Sidransky E, Fartasch M, Lee RE, Metlay LA, Abella S, Zimran A, Gao W, Elias PM, Ginns EI, Holleran WM (1996) Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease. Pediatr Res 39:134–141CrossRefPubMed Sidransky E, Fartasch M, Lee RE, Metlay LA, Abella S, Zimran A, Gao W, Elias PM, Ginns EI, Holleran WM (1996) Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease. Pediatr Res 39:134–141CrossRefPubMed
go back to reference Whitfield PD, Nelson P, Sharp PC, Bindloss CA, Dean C, Ravenscroft EM, Fong BA, Fietz MJ, Hopwood JJ, Meikle PJ (2002) Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity. Mol Genet Metab 75(1):46–55CrossRefPubMed Whitfield PD, Nelson P, Sharp PC, Bindloss CA, Dean C, Ravenscroft EM, Fong BA, Fietz MJ, Hopwood JJ, Meikle PJ (2002) Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity. Mol Genet Metab 75(1):46–55CrossRefPubMed
go back to reference Xu YH, Quinn B, Witte D, Grabowski GA (2003) Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol 163:2093–2101PubMed Xu YH, Quinn B, Witte D, Grabowski GA (2003) Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol 163:2093–2101PubMed
Metadata
Title
Gaucher disease in sheep
Authors
Litsa Karageorgos
Malcolm J. Lancaster
Judith S. Nimmo
John J. Hopwood
Publication date
01-02-2011
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 1/2011
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-010-9230-3

Other articles of this Issue 1/2011

Journal of Inherited Metabolic Disease 1/2011 Go to the issue

Homocysteine and B-Vitamin Metabolism

Choline and betaine in health and disease

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.